The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication - Pub
3 hours ago
- #enzalutamide
- #dalpiciclib
- #prostate cancer
- Combining the CDK4/6 inhibitor dalpiciclib with enzalutamide enhances antitumor effects in castration-resistant prostate cancer models.
- The combination inhibits cell cycle progression, migration, DNA replication, and promotes apoptosis.
- Enzalutamide blocks AR-mediated activation of MCM4, enhancing CDK4/6 inhibition and DNA replication disruption for synergy.